ctDNA testing for response in first-line PCNSL treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether a blood test (ctDNA) can help doctors see how well treatment is working for people with a type of brain lymphoma (PCNSL) who are getting their first treatment with a cure in mind.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have been diagnosed with diffuse large B-cell lymphoma that is only in the brain or spinal cord (not elsewhere in the body)
- You have not had any prior treatment for this lymphoma (except steroids, which are okay)
- You are healthy enough to receive standard full-dose chemotherapy (like MATRix) aimed at curing the disease
- You can give informed consent (or a family member can do so if you are temporarily unable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
This study looks at how primary central nervous system (CNS) lymphoma can be identified and tracked using scans and molecular (tissue/biomarker) tests. It may help doctors better understand your disease and choose the best next steps.
This study collects blood, cerebrospinal fluid, and tumor tissue samples over time from people with suspected or confirmed primary central nervous system lymphoma (PCNSL) in China. The goal is to build a large biobank to better understand the disease and improve future diagnosis and treatment.
This study collects and analyzes tumor samples from people diagnosed with a type of brain lymphoma to learn more about the disease and improve future treatments.
This study uses brain biopsy and spinal fluid (lumbar puncture) tests to better diagnose and understand how well treatments may work for certain lymphomas in the brain. It may help doctors match the right therapy by studying what the disease looks like in the body and brain.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
Hear when a new Primary Central Nervous System (CNS) Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.